A small clear glass bottle of fine white research powder beside a few unbranded white capsules on a clean white laboratory bench, with softly blurred clinical glassware behind it.

5-Amino-1MQ: The NNMT-Blocking Molecule Chasing Fat Loss & Metabolism

Updated 2026-06-16T00:00:00.000Z19 min read · 4,989 words

5-Amino-1MQ is a small experimental molecule that blocks an enzyme called NNMT, and in obese mice that single change drove fat loss while sparing muscle. That mouse result is the entire reason it has become a buzzy "fat-loss peptide" in the biohacking world, where it now shows up on most best peptides for longevity shortlists. The honest catch is bigger than the hype: 5-Amino-1MQ is not a peptide at all, it has barely been tested in people, and it is sold only as an unapproved research chemical.

The first thing to clear up is the "peptide" label. Despite being sold next to BPC-157 and tirzepatide on the same research-chemical sites, 5-Amino-1MQ is a tiny synthetic small molecule, taken as an oral capsule rather than injected, and it works by inhibiting an enzyme, not by mimicking a hormone. This guide is the high-level map of the whole compound: what it is, how blocking NNMT indirectly raises NAD+ and SAM, what the mouse evidence actually shows, the huge human-data gap, the doses people report, and its research-only legal status. Each section is an overview; the deep-dive spokes (full dosing, stacking, the NAD+ comparison) link out so this page stays a clean hub.

Key Takeaways

  • 5-Amino-1MQ is a small molecule, not a peptide. It is 5-amino-1-methylquinolinium, a selective inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT), taken orally as capsules, not injected (PubChem, CID 950107, retrieved 2026-06-16).
  • It raises NAD+ indirectly. By blocking NNMT, it stops that enzyme from consuming nicotinamide (an NAD+ precursor) and the methyl donor SAM, so more of both stay available inside fat and liver cells (Nature, 2014, retrieved 2026-06-16).
  • The fat-loss reputation is from mice. A 2018 study showed a selective small-molecule NNMT inhibitor reduced body weight and white-fat mass in diet-induced obese mice without changing how much they ate (Biochemical Pharmacology, 2018, retrieved 2026-06-16).
  • There are essentially no completed human trials. As of 2026, the human efficacy file is effectively empty; everything practical is extrapolated from animal data and clinic anecdote, not validated in people (Biochemical Pharmacology, 2018, retrieved 2026-06-16).
  • Reported oral doses cluster around 50-150 mg per day in capsules, run in cycles. These are community/clinic conventions, not an established or recommended human dose, and there is no approved label behind them.
  • It is not FDA-approved and is sold "for research use only." It is not a dietary ingredient, has no legitimate U.S. prescription or compounding route, and athletes should treat metabolic modulators as a doping risk even where a substance is not explicitly named.

What is 5-Amino-1MQ?

5-Amino-1MQ is a small synthetic molecule that blocks the enzyme NNMT, studied in animals for fat loss and metabolic health — and despite being sold in the "peptide" market, it is not a peptide. Its full chemical name is 5-amino-1-methylquinolinium, and it is taken by mouth as a capsule rather than injected. It is studied mostly for reducing fat mass and supporting cellular energy metabolism.

Chemically, 5-Amino-1MQ is a methylquinolinium small molecule (molecular formula C10H11N2+, PubChem CID 950107), not a chain of amino acids (PubChem, "5-Amino-1-methylquinolinium", retrieved 2026-06-16). That distinction matters more than it sounds. A peptide like BPC-157 is a short protein fragment that usually has to be injected because stomach acid would destroy it; 5-Amino-1MQ is a stable small molecule that survives digestion, which is exactly why it works as an oral capsule. It was designed in academic and biotech drug-discovery programs specifically to inhibit one enzyme, NNMT, selectively. If the peptide-versus-small-molecule distinction is new to you, our how peptides work guide lays out the difference.

The single most important fact about 5-Amino-1MQ is its status: it is not approved by the FDA or any other drug regulator for any use. It exists in a modest body of preclinical research and, separately, in a large unapproved "research chemical" market. Everything else in this guide should be read through that lens.

Citation capsule. 5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), not a peptide. Molecular formula C10H11N2+; PubChem CID 950107. It is taken orally, is studied preclinically for fat loss and metabolic health, and is not approved by any regulator for human use. Source: PubChem, CID 950107, 2026; Neelakantan et al., Biochemical Pharmacology, 2018.

A small clear glass bottle of fine white research powder beside a few unbranded white capsules on a clean white laboratory bench, with softly blurred clinical glassware behind it.

How does 5-Amino-1MQ work?

5-Amino-1MQ works by blocking the enzyme NNMT, which normally burns through two valuable cell resources — an NAD+ building block and the methyl donor SAM — so inhibiting it leaves more of both inside fat and liver cells, nudging them to burn energy instead of store it. In other words, it raises NAD+ indirectly, by stopping a drain rather than adding fuel. This whole picture comes from animal and cell studies, not human trials.

Here is the plain-English version. NNMT (nicotinamide N-methyltransferase) takes nicotinamide, which is a precursor your cells can recycle back into NAD+, and permanently methylates it into 1-methylnicotinamide, a molecule that gets excreted. To do that, it also uses up SAM (S-adenosylmethionine), the cell's main methyl donor (Wikipedia, "Nicotinamide N-methyltransferase", retrieved 2026-06-16). When NNMT runs hot — and it runs especially hot in the fat cells of insulin-resistant animals — it siphons off nicotinamide and SAM. Block the enzyme, and both pools recover: more nicotinamide can be salvaged back to NAD+, and SAM stays available for normal methylation.

That recovered NAD+ matters because it fuels sirtuins (such as SIRT1), the "longevity" enzymes that support mitochondrial activity and energy expenditure. The original 2014 genetic study put it directly: silencing NNMT in fat and liver "protects against diet-induced obesity by augmenting cellular energy expenditure," and it does so by "increasing adipose SAM and NAD+ levels" (Nature, "Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity", 2014, retrieved 2026-06-16). So the chain is: block NNMT, spare NAD+ and SAM, raise energy expenditure inside fat cells.

A crucial honesty note on the NAD+ angle: 5-Amino-1MQ does not supply NAD+ the way an NAD+ IV drip or an NMN/NR supplement does. It raises NAD+ only by closing a leak. For the full picture of NAD+ itself — what it is, the direct precursor routes, and what is actually proven in humans — see our NAD+ therapy guide. We keep NAD+ shallow here on purpose so this hub stays about the NNMT-inhibitor angle.

A conceptual photorealistic image of glowing blue and amber points of light clustered inside a translucent human midsection, suggesting fat cells switching toward energy-burning metabolism, with a soft clinical depth of field.

How 5-Amino-1MQ is proposed to work (preclinical)Block the enzyme, spare the fuel5-Amino-1MQ raises NAD+ indirectly, by stopping a drain. From animal and cell studies.5-Amino-1MQblocks NNMT enzymeNicotinamide sparedrecycled to NAD+SAM sparedmethyl donor preservedNAD+ fuels sirtuins+ mitochondriamore energy burned in fatSource: Nature, 2014; Biochemical Pharmacology, 2018. Not confirmed in humans.
5-Amino-1MQ's proposed mechanism: it inhibits NNMT, sparing nicotinamide and SAM so NAD+ recovers and fat cells burn more energy. Supported by preclinical data; not confirmed in human trials.

What is 5-Amino-1MQ used for?

5-Amino-1MQ is studied and used mainly for fat loss and metabolic health, with secondary interest in muscle preservation, energy, and the broader "raise NAD+" longevity angle. None of these are FDA-approved uses; they are the directions mouse research and clinic anecdote have pointed.

The headline use is body-fat reduction. In animal models, inhibiting NNMT shrank fat mass and lowered body weight, and notably did so without the animals eating less — the effect was attributed to fat cells burning more energy, not appetite suppression (Biochemical Pharmacology, 2018, retrieved 2026-06-16). That "fat down, food intake unchanged" profile is what makes it sound different from a GLP-1 drug, which works largely by reducing appetite. The same animal work also reported preserved lean mass and lower plasma cholesterol, which is where the "lose fat, keep muscle" and metabolic-health framing comes from.

A quick overview of the areas 5-Amino-1MQ is studied for, and where the evidence stands:

Studied areaWhat preclinical research suggestsEvidence level
Fat lossReduced body weight and white-fat mass; smaller fat cellsMouse studies; no completed human trials
Energy expenditureHigher cellular energy burn without eating lessMouse / cell studies
Muscle / lean massLean mass preserved while fat droppedMouse studies
Insulin sensitivityImproved glucose handling in obese modelsMouse studies
LipidsLower plasma total cholesterolMouse studies
NAD+ / longevity angleIndirectly raises NAD+ by blocking its drainMechanistic; human relevance unproven

Because each of these is a distinct future spoke, we keep them brief here. The honest headline: 5-Amino-1MQ looks genuinely interesting across metabolism in mice, but the human evidence has not even begun to catch up to the marketing.

How strong is the evidence for 5-Amino-1MQ?

The evidence for 5-Amino-1MQ is almost entirely preclinical: a clear, encouraging mouse-and-cell story, and essentially no completed human clinical trials. That gap between promising rodent results and a near-empty human file is the single most important thing to understand before considering it.

The foundation is two studies. First, a 2014 Nature paper showed that genetically knocking down NNMT in fat and liver protected mice from diet-induced obesity by raising adipose SAM and NAD+ and increasing energy expenditure (Nature, 2014, retrieved 2026-06-16). That was a proof of concept that the enzyme was a real metabolic target. Second, and more directly, a 2018 paper in Biochemical Pharmacology translated that into a drug: a "selective and membrane-permeable small molecule inhibitor of nicotinamide N-methyltransferase" — the 5-Amino-1MQ class — that "reverses diet-induced obesity in mice," reducing body weight and white-adipose mass while leaving food intake unchanged (Biochemical Pharmacology, "Selective and membrane-permeable small molecule inhibitors of NNMT reverse high fat diet-induced obesity in mice", 2018, retrieved 2026-06-16).

Why the human evidence is essentially missing

It helps to be blunt about how thin the human file is: as of 2026, there are no published, completed, results-reported human efficacy trials of 5-Amino-1MQ for fat loss. The entire practical reputation rests on the mouse studies above plus anecdote from longevity and wellness clinics. There is also almost no human pharmacokinetic data — we do not really know how much of an oral capsule is absorbed, how long it lasts, or how it is cleared in people. That missing human picture is exactly why every dose figure in this guide can only be a reported convention rather than a validated number. Mouse metabolism is not human metabolism, and a long history of obesity compounds that dazzled in rodents and disappointed in people is reason for real caution.

Our take: The most common mistake we see is reading "raises NAD+ and burns fat" as if it were a human result. It is a mouse result with a plausible mechanism. The 2014 and 2018 studies are genuinely good science, but they are preclinical, and "investigational" — closer to "promising in mice" than "proven in people" — is the honest label for 5-Amino-1MQ in 2026.

5-Amino-1MQ evidence base: a mouse story, no human trialsWhere the evidence actually isThe research is real, but it is preclinical. Bars are illustrative of scale.MultipleMouse / cell studies0Completed human trialsIllustrative of scale. Source: Nature, 2014; Biochemical Pharmacology, 2018.
The defining feature of 5-Amino-1MQ evidence is the imbalance: an encouraging preclinical literature and no completed human efficacy trials.

What doses of 5-Amino-1MQ do people report using?

There is no validated dose for 5-Amino-1MQ, but reported clinic and community protocols cluster around 50 to 150 mg per day as oral capsules, usually run in cycles. These are figures people report, not an established or recommended dose, and because no human trial has done dose-finding, there is no approved label to anchor them.

The most commonly cited range is 50-150 mg per day by mouth, often started low (around 50 mg) and assessed over a few weeks, and frequently cycled rather than taken continuously. Because the compound is oral and a stable small molecule, no reconstitution or injection is involved — you simply swallow a capsule, which is part of why it appeals to people who avoid needles. We label all of this as a community/clinic convention because no regulator has reviewed a dose and the underlying human pharmacokinetics are essentially unstudied (Biochemical Pharmacology, 2018, retrieved 2026-06-16). For orientation only, here is how people commonly describe the reported use (not a recommendation):

FormatReported amountNotes
Oral capsule50-150 mg/dayMost common; often split into 1-2 doses
Starting point~50 mg/dayFrequently described as a conservative on-ramp
Cycle lengthSeveral weeks, then a breakUsually cycled, not continuous

Note that some vendors also list a subcutaneous-injection microgram dose; that is a minority practice and still rests on the same absent human data. The detailed titration ladder, cycling rationale, and the popular fat-loss stacks (for example with GLP-1 compounds or growth-hormone secretagogues) are dedicated spokes — keeping them here would cannibalize those future articles. We cover only the high-level framing and link out to the how to vet research-compound quality guide for sourcing and the legal status overview.

Our take: Numbers like "100 mg a day" get repeated across vendor blogs until they sound official. They are not. They are clinic and community conventions extrapolated from mouse dosing and practitioner habit, not human dose-finding trials, which is exactly why we never present them as a validated dose.

5-Amino-1MQ as a share of all ProtocolPlus tracking activityAn emerging niche, by tracking volumeShare of all logged doses in the app. A popularity signal, not an endorsement.0.8%of all logged doses5-Amino-1MQ1,800 logged doses · 288 trackersAll other compounds231,868 of 233,668 total dosesProtocolPlus app data (Sep 2024-Jun 2026): 1,800 of 233,668 logged doses. Oral compound, no vial stats.
ProtocolPlus tracking: 5-Amino-1MQ is ~0.8% of all logged doses (1,800 of 233,668), an emerging niche fat-loss compound rather than a mainstream one. A popularity signal, not an endorsement.

What are the side effects of 5-Amino-1MQ?

Because 5-Amino-1MQ has essentially never been tested in humans, its real side-effect profile is unknown; the few clues come from mouse studies that reported no obvious adverse effects, plus theoretical concerns researchers raise about disturbing methylation and NAD+ balance. "Unknown" is the honest headline here, not "safe."

In the animal work, the selective NNMT inhibitor was reported to reduce fat without observable adverse effects, and the inhibitors were highly selective — they did not block other SAM-dependent methyltransferases or NAD+ salvage enzymes in testing (Biochemical Pharmacology, 2018, retrieved 2026-06-16). That selectivity is reassuring as far as it goes, but it is mouse data at research doses, not human safety. A hub-level overview of what is reported and what is theorized:

  • Commonly reported (anecdotal, mild): mild gastrointestinal upset, headache, or changes in energy or sleep — all from user reports, not controlled data.
  • Quality-related risks: because the market is unregulated, contamination, mislabeled potency, or impurities are real concerns independent of the molecule itself.
  • Theoretical, mechanism-based: NNMT sits at the crossroads of NAD+ and methylation (SAM) chemistry, so researchers flag that strongly shifting those pools long-term could have effects we cannot yet predict in humans.
  • Unknown: true long-term human safety, drug interactions, and effects in people with metabolic disease — because the human data simply do not exist.

This is the hub-level summary; we do not have a validated human safety profile to detail. Anyone weighing it should treat the absence of human safety data as a risk in itself, not as reassurance.

How does 5-Amino-1MQ compare to NAD+ therapy?

5-Amino-1MQ and NAD+ therapy both aim to raise NAD+, but by opposite logic: 5-Amino-1MQ blocks the enzyme (NNMT) that drains NAD+'s precursor, while NAD+ therapy (IV drips, or NMN/NR precursors) tries to supply NAD+ or its building blocks directly. Both are popular in longevity circles, and neither has the kind of large human trials that would settle whether they meaningfully raise NAD+ inside your tissues.

The cleanest way to hold them apart is "stop the leak" versus "add water to the tank." 5-Amino-1MQ does not contain NAD+ or any precursor; it simply stops NNMT from methylating nicotinamide away, so more can be salvaged back into NAD+ and more SAM stays free. NAD+ therapy takes the direct route — an IV of NAD+ itself, or oral NMN/NR precursors — to push the levels up from the supply side. The two are sometimes even discussed together for that reason, but they are mechanistically different interventions with different open questions. People weighing 5-Amino-1MQ against another mitochondrial fat-loss candidate often look at our MOTS-c vs 5-Amino-1MQ head-to-head as well.

This is a deliberately brief hub-level contrast, because the full NAD+ story — whether IV NAD+ actually reaches your cells, how NMN and NR compare, and what is genuinely proven in humans — is its own large topic and would cannibalize that article if we ran it here. For the complete picture, see our full NAD+ therapy guide. The shared honest caveat is the same for both: the human evidence that any of these reliably "raises NAD+ and reverses aging" is far thinner than the marketing suggests.

5-Amino-1MQ is not approved by any regulator, so there is no official safety determination, and it is not legal to sell or prescribe as an approved medicine or to include in dietary supplements; the products sold online are unapproved "research chemicals." That status matters more than any single study.

On safety, the mouse data look encouraging for an investigational compound, but "no adverse effects in mice at research doses" is not the same as "established safe in humans," and there is essentially no human safety record to point to. On legality, the U.S. picture is clear: 5-Amino-1MQ is not an FDA-approved drug, it is not a lawful dietary ingredient, and it has no legitimate prescription or over-the-counter route. Unlike some peptides, it is not even on the FDA's 503A interim bulk-drug-substances list, meaning there is no recognized compounding pathway for it either. In practice it is sold strictly "for research use only, not for human consumption."

For athletes, treat it cautiously. As of the 2026 WADA Prohibited List, 5-Amino-1MQ is not explicitly named, but the Prohibited List is not exhaustive, and a fat-loss agent that acts as a metabolic modulator is the kind of substance that can fall under a broader prohibited category (WADA, "2026 Prohibited List", 2026, retrieved 2026-06-16). Tested athletes and service members should assume risk and check current rules rather than relying on the absence of a name. For the full legal framework and how to evaluate a vendor, see are peptides legal and how to vet peptide quality.

Our take: The single most common misunderstanding is assuming that because 5-Amino-1MQ is sold openly online and "raises NAD+," it must be a vetted supplement. It is not. It is an unapproved research chemical with no human safety file and no legal route for human use. Easy to buy is not the same as proven, legal, or safe.

A photorealistic still life on a wellness clinic desk: a small clear glass bottle and a few unbranded white capsules beside a glass of water on a light wooden surface in warm natural morning light.

How do people obtain 5-Amino-1MQ?

Because 5-Amino-1MQ is unapproved, the main way people access it is by buying unapproved "research chemical" capsules or powder online, which is a legal and safety gray market with no quality oversight. There is no legitimate prescription or compounding route for it outside of formal research.

The research-compound market is where most online searches end up: vendors sell 5-Amino-1MQ capsules or bulk powder "for research use only," and buyers use it off-label. That market carries real risks of mislabeled potency, impurities, and non-sterile product, with no regulator checking what is actually in the bottle. If you are researching that path despite the risks, the responsible groundwork is the same as for any research compound:

  1. Confirm the legal status for your country, sport, and workplace before anything else. See are peptides legal.
  2. Demand a certificate of analysis (COA) from independent third-party testing, and learn to read it for identity and purity. See how to vet peptide quality.
  3. Understand what you are actually taking — a small molecule that shifts NAD+ and methylation chemistry, with no human safety data behind it.
  4. Talk to a qualified clinician who can weigh your specific health situation, medications, and metabolic risks.

We are describing what people do, not endorsing it. Using an unapproved research compound means accepting unknown risks with no regulatory safety net.

A realistic look at expectations

The "lose fat without dieting" promise around 5-Amino-1MQ comes from mice, not from controlled human results, so realistic expectations should be modest and skeptical. Going in calibrated is part of using any of this information responsibly.

Two honest caveats sit on top of the hype. First, the striking mouse finding — fat loss without eating less — has not been reproduced in a published human efficacy trial, and obesity research is littered with compounds that worked in rodents and underwhelmed in people. Second, much of what people attribute to 5-Amino-1MQ in clinics overlaps with the diet, training, and other compounds they are using at the same time, which makes it very hard to credit the molecule itself without controlled data. For grounded context on reading transformation claims, see how these compounds work.

Frequently Asked Questions

No. Despite being sold in the peptide market, 5-Amino-1MQ (5-amino-1-methylquinolinium) is a small synthetic molecule, not a chain of amino acids. It is taken orally as a capsule rather than injected, and it works by inhibiting the enzyme NNMT rather than mimicking a hormone.

The bottom line

5-Amino-1MQ is one of the more scientifically interesting compounds in the current fat-loss conversation, and also one of the most over-sold. Its mechanism is elegant: block one enzyme, NNMT, and you spare both NAD+ precursor and the cell's methyl donor, which in mice pushed fat cells to burn more energy and shed fat without the animals eating less. The 2014 Nature and 2018 Biochemical Pharmacology studies behind that idea are real, careful science.

The other half of the story is discipline. 5-Amino-1MQ is a small molecule sold as a "peptide," it has essentially no completed human trials, no validated dose, no human safety record, and no legal route for human use — it is an unapproved research chemical. The honest label is investigational, and arguably "promising in mice" is more accurate than "investigational" implies in humans. If you take one thing from this hub, let it be the distance between a clean mouse result and a proven human therapy, and the value of a qualified clinician in navigating it. From here, the natural next reads are our NAD+ therapy guide, are peptides legal, and how to vet peptide quality.

Sources